D. Ross Camidge

Following a PhD in Molecular Biology at the Medical Research Council’s Laboratory of Molecular Biology at Cambridge University, UK, Dr Camidge completed his medical training at Oxford University, UK. He then became the first person to double train in Medical Oncology and Clinical Pharmacology in the UK, before joining the University of Colorado, USA from October 2005.

Dr Camidge’s main clinical and research interests are thoracic malignancies and developmental therapeutics. The discoveries he and his team have made have changed the standard of care for the treatment of lung cancer multiple times. He has authored over 250 academic publications, including in the Journal of Thoracic Oncology, Lancet Oncology, and New England Journal of Medicine. He has received numerous awards including the Bonnie J. Addario International Lectureship Award and The Lung Cancer Foundation’s Breath Away From The Cure Award. Every year from 2017, he has been internationally recognized as a highly cited researcher ranked in the top 1% of all of Clinical Medicine by Clarivate Analytics Web of Science. In 2019 and 2020 he was ranked at the ‘World Expert’ level by Expertscape and recognized to be in the top 0.0043% of scholars writing about Lung Neoplasms over the past 10 years. He is also the National Medical Director of the Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC) – a collaborative network of 15 US and Canadian sites conducting trials in thoracic oncology, Co-chair of the Elsevier ClinPath (formerly VIA) Oncology Lung Cancer Pathways Committee and a past-member of the National Comprehensive Cancer Network Lung Cancer Committee.